Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883520 | 0.82 | DPP8 (0.33) | FAAHSLC18A3KDM4ECYP2C19L3MBTL1 | |
| SCHEMBL2878241 | 0.79 | OPRL1 (0.40) | FAAHKDM4ECYP2C19IDH1L3MBTL1 | |
| SCHEMBL2147611 | 0.76 | CHRM4 (0.41) | — | |
| SCHEMBL3312248 | 0.73 | HDAC1 (0.44) | — | |
| SCHEMBL10286472 | 0.73 | HDAC1 (0.44) | — | |
| SCHEMBL4713765 | 0.72 | HDAC1 (0.43) | — | |
| SCHEMBL924248 | 0.72 | CYP2C19 (0.42) | ALOX15KDM4ECYP2C19L3MBTL1 | |
| SCHEMBL2880299 | 0.69 | OPRL1 (0.35) | FAAHKDM4ECYP2C19IDH1OPRL1 | |
| SCHEMBL17768596 | 0.69 | KDM4E (0.36) | SLC18A3KDM4EGABRA1GABRB2L3MBTL1 | |
| SCHEMBL369170 | 0.68 | KDM4E (0.41) | TSHRALOX15FAAHKDM4ECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | TSHR 213/4885ALOX15 1018/4885FAAH 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.